Latest Ratios: P/E Ratio -7.1x · EV/EBITDA N/A · ROE -36.0%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $1M | $3M | $5M | — | — | — |
| Enterprise Value | $5M | $-451644 | $1M | $2M | — | — | — |
| P/E Ratio → | -7.14 | — | — | — | — | — | — |
| P/S Ratio | 0.85 | 0.14 | 0.37 | 0.90 | — | — | — |
| P/B Ratio | 3.05 | 0.49 | 1.04 | 1.23 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.06 | 0.13 | 0.35 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 34.4% | 34.4% | 20.7% | 25.5% | 18.9% | 30.5% | — |
| Operating Margin | -12.5% | -12.5% | -47.2% | -52.4% | -37.2% | -0.2% | — |
| Net Profit Margin | -12.4% | -12.4% | -47.1% | -53.3% | -37.7% | -0.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -36.0% | -36.0% | -109.1% | -124.4% | -602.6% | — | — |
| ROA | -27.8% | -27.8% | -87.4% | -81.1% | -148.3% | -1.2% | -142.2% |
| ROIC | -86.8% | -86.8% | -294.7% | -165.1% | -167.0% | -2.1% | — |
| ROCE | -35.0% | -35.0% | -106.4% | -120.7% | -487.2% | -8.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.16 | 0.06 | 1.32 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.70 | -0.68 | -0.76 | 1.31 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -68.15 | -68.15 | -239.98 | -53.73 | -73.24 | — | — |
Net cash position: cash ($2M) exceeds total debt ($143787)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 4.06 | 4.06 | 5.46 | 5.25 | 0.92 | 0.84 | 0.42 |
| Quick Ratio | 4.06 | 4.06 | 5.46 | 5.25 | 0.89 | 0.84 | 0.42 |
| Cash Ratio | 2.39 | 2.39 | 3.90 | 3.60 | 0.00 | 0.22 | 0.42 |
| Asset Turnover | — | 2.61 | 2.17 | 1.12 | 2.42 | 2.63 | — |
| Inventory Turnover | — | — | — | — | 96.51 | — | — |
| Days Sales Outstanding | — | 46.39 | 31.13 | 78.38 | 87.47 | 73.04 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $12M | $7M | $5M | $7M | $7M | $6M |
Capital exhaustion and dilution
Based on reported figures, SYRA trades at a P/S ratio of 0.85, which appears to reflect a market pricing the company as a distressed service provider rather than a high-growth health-tech entity, given the lack of positive earnings and the absence of a meaningful forward P/E multiple.
The current valuation multiple suggests that investors are heavily discounting the company's digital health pivot, likely due to the persistent negative earnings and the volatility of its government-contract-dependent revenue. Without a clear path to profitability, the P/S ratio serves as a poor proxy for value, as it fails to account for the significant capital requirements needed to sustain the Syrenity platform's development.
As reported in financial statements, SYRA's ROIC has remained consistently negative, bottoming out at -163.7% in 2024Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its investments in staffing and digital health infrastructure.
The inability to generate positive returns on invested capital suggests that the company's core business model is not yet self-sustaining. Investors should monitor whether the recent improvement in ROIC to 2.0% in 2026Q1 represents a structural shift toward efficiency or merely a temporary fluctuation driven by non-recurring working capital adjustments.
According to recent SEC filings, SYRA's asset turnover has remained stagnant between 0.37 and 0.68, suggesting that the company is struggling to extract meaningful revenue from its existing asset base, a trend that is further complicated by erratic DSO levels that peaked at 60 days.
The high variability in DSO and the lack of a consistent cash conversion cycle indicate that the company lacks leverage over its government and institutional clients. This inefficiency in collecting receivables forces the company to maintain higher liquidity buffers, which in turn pressures the overall return on assets.
Based on the most recent quarterly data, SYRA's current ratio of 2.48 provides a superficial sense of security, yet this is undermined by the company's persistent negative net margins and a cash position of only $1.6M, which warrants significant concern regarding near-term solvency.
While the current ratio appears adequate compared to historical levels, it does not account for the high burn rate associated with the company's R&D and corporate overhead. The lack of a quick ratio buffer suggests that any delay in government contract payments could lead to an immediate liquidity crisis.
The most commonly misapplied metric for SYRA is the P/S ratio, which obscures the company's underlying cash burn and the high cost of customer acquisition inherent in its government-focused, labor-intensive business model, leading to an overestimation of the firm's intrinsic value.
Analysts should instead focus on the cash burn rate relative to the remaining cash balance, as this provides a more accurate assessment of the company's survival horizon. Relying on revenue multiples for a firm that is currently losing money on every dollar of sales ignores the reality that the company's primary challenge is not growth, but capital preservation.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SYRA stock.
Syra Health Corp. Class A Common Stock's current P/E ratio is -7.1x. This places it at the 50th percentile of its historical range.
Syra Health Corp. Class A Common Stock's return on equity (ROE) is -36.0%. The historical average is -89.8%.
Based on historical data, Syra Health Corp. Class A Common Stock is trading at a P/E of -7.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Syra Health Corp. Class A Common Stock has 34.4% gross margin and -12.5% operating margin.